Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy

Abstract

Drisapersen 6 mg/kg/week for 24 weeks resulted in a treatment benefit in 6MWD, largely maintained 24 weeks off-treatment. This study provided insights for further studies to optimize dosage regimen.